Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Technology Development: Page 2
Satio partners with nonprofit institute in Senegal
By
LabPulse.com staff writers
Under the deal, the company's SatioRx intradermal patches will be combined with Institut Pasteur de Dakar technologies to drive clinical development and access to vaccine patches. The partnership will also encompass diagnostic patches for blood sampling, genetic testing, and pathogen surveillance, Satio said.
August 22, 2022
FYR Dx, Medicover partner on assay, tech development
By
LabPulse.com staff writers
The firms plan to support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.
August 16, 2022
Nucleai, Ultivue to partner on AI-based drug development platform
By
LabPulse.com staff writers
Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.
June 5, 2022
Hitachi High-Tech partners, invests in Invivoscribe
By
LabPulse.com staff writers
The partnership brings together Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory knowledge and Hitachi High-Tech's experience in measurement and analysis systems technologies.
May 9, 2022
New task force promotes pathology for cancer research
By
LabPulse.com staff writers
Efforts of the task force include an award program for outstanding pathology research in cancer, knowledge hubs on pathology for medical students, and the development and adoption of new technologies in pathology. Parwani shed light on the new task force in an interview with LabPulse at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
Huron Digital taps Audil Virk as president
By
LabPulse.com staff writers
Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.
April 14, 2022
MilliporeSigma closes Exelead buy for lipid nanoparticle boost
By
LabPulse.com staff writers
MilliporeSigma plans to invest more than $565Â million over the next 10 years to further expand Exelead's PEGylated research and development and its LNP-based drug delivery technology, which is key to mRNA vaccines and therapeutics, MilliporeSigma said.
February 22, 2022
SLAS 2022: Diagnostics tech should be based on clinical need
By
Leah Sherwood
Traditionally, scientists and engineers create a technology, find a biological application for it, and publish it in a big academic journal. For companies, the cycle is a bit different: a company creates a technology, most likely for life sciences research, and then years (if not decades) later, someone discovers a clinical application for it.
February 9, 2022
DiaCarta, NCI to work on cancer detection technology
By
LabPulse.com staff writers
Under a two-year Cooperative Research and Development Agreement (CRADA), the organizations will work on investigating low-frequency mutation events in cancers and rare diseases using DiaCarta's technology, as well as develop xenonucleic acid probes for in situ cancer cell detection.
January 6, 2022
NIH announces accelerator diagnostics challenge
By
LabPulse.com staff writers
The contest aims to spur and reward the development of prototypes for low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies, the agency said in a release.
December 6, 2021
Point-of-care developer DCN Dx acquires IVD Vision
By
LabPulse.com staff writers
DCN Dx is a leading specialist developer of diagnostic tests based on lateral flow technology. The acquisition expands DCN Dx's POC diagnostics development services capabilities and product portfolio.
July 1, 2021
Expanding NIPT coverage means nominal cost increase
By
LabPulse.com staff writers
HPHC, which covers around 3Â million people in the northeastern U.S., partnered with Illumina and the University of Colorado for the study, which evaluated the effect of a risk-sharing agreement that opened insurance coverage for these women. For the agreement, Illumina and HPHC engaged the University of Colorado as a third-party academic collaborator in 2018 to develop a study protocol, complete the analyses, and lead the publication development. The PharmacoEconomics article is the first-ever published report on a value-based agreement between a bio/medical technology company and a payer, the groups said in a press release.
March 11, 2021
Previous Page
Page 2 of 4
Next Page